Osteolytic bone disease caused by secretion of PTHrP also involves stimulation of osteoclasts that in turn secrete tumour-activating transforming growth factor beta which further stimulates local cancer cells in the setting of metastatic disease [2]. Here, PTHLH is linked to neoplasm.